Skip to content

Phase I Split-Belt Treadmill Dosing for Subacute Stroke

NeuroRecoVR: Phase I Split-Belt Treadmill Dosing for Subacute Stroke

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07469163
Enrollment
72
Registered
2026-03-13
Start date
2026-03-01
Completion date
2026-08-31
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Stroke Gait Rehabilitation, Stroke (Subacute), Subacute Stroke

Keywords

stroke, subacute stroke, split belt treadmill, gait rehabilitation, stroke recovery

Brief summary

After experiencing a stroke, many individuals encounter difficulties with walking and balance, which can significantly impact their independence. Recent studies have indicated that split-belt treadmill (SBT) training is effective for improving gait metrics, including walking speed and step length asymmetry. The SBT allows each leg to move at different speeds, which has been shown to help chronic stroke survivors learn to walk more symmetrically. However, there is limited knowledge about the dose participants should receive and the safety of SBT training in the early stages of recovery, which is a crucial period for rehabilitation. To address this gap, we are evaluating an innovative SBT with virtual reality (VR) features at the Foothills Medical Center. Our objective is to conduct a study to determine the amount of SBT training patients can tolerate in a day. In this study, stroke survivors will engage in a series of walking exercises on the SBT. We will escalate the duration of SBT walking until participants reach a point where they can no longer continue due to dose-limiting criteria such as fatigue or discomfort. The findings from this initial phase will guide future larger trials to explore the effectiveness of this training method. Ultimately, we aspire to improve rehabilitation strategies for stroke survivors, assisting them in regaining mobility and enhancing their quality of life more effectively.

Interventions

Participants undertake 5 days of treadmill walking. Each day is broken into 3 episodes: A) two-minutes tied-belt walking, B) n minutes split-belt walking (dose escalating component), C) 10-minutes tied-belt walking. Split-belt walking will start at a dose of 8-minutes and escalate by 3 minute increments, up to a maximum dose of 30 minutes.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE

Intervention model description

This is a Phase I dose-ranging trial utilizing a rule-based A+B design. The primary goal of this investigation is to employ a dose escalation paradigm to ascertain the maximum tolerated dose of split-belt walking in a day. For each investigated dose, three participants (A) are recruited. If all participants tolerate the dose, three more participants (A) are recruited and enrolled at the next available dose. If dose limiting criteria is met for one of the three participants (A), three more participants (B) are recruited and enrolled at the current dose.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ischemic or hemorrhagic stroke survivors * First stroke * Over 18 years old * Between one week and three months post-stroke * can understand task instructions.

Exclusion criteria

* History of significant neurological diseases (e.g. Multiple Sclerosis, Parkinson's disease) * Orthopedic issues in lower extremities (e.g. severe knee Osteoarthritis) * Excessive pain preventing participants from participating in treadmill-based activities * Cerebellar stroke * Body weight more than 560 lbs (this exceeds the weight limit of the support harness)

Design outcomes

Primary

MeasureTime frameDescription
Dose Tolerability5 daysDose tolerability, defined as the presence, or lack thereof, any of the following dose-limiting criteria: * Participant requests to stop/declines to participate in any more sessions during the intervention period * Participant requests to stop before completing ≥80% of a session, 2+ times during the intervention period, for an intervention-related reason * Unfeasible to deliver ≥80% of a session, two or more times during the intervention period for organizational or environmental constraints * Unable to complete activities of their daily routine within 24 hours after their session * Therapist requests to stop before completing ≥80% of a single session 1+ times during the intervention period due to therapist fatigue * Participants cannot ramp up to the intended dose level within 3 days. * The therapist requests to stop before completing ≥80% of a single session 1+ times during the intervention period due to poor walking quality * Participant experiences attributable adverse event

Countries

Canada

Contacts

CONTACTAlexa Boyer
alexa.boyer1@ucalgary.ca5193594643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026